InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

Pre-tax losses at the main Irish unit of eye care product firm Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.

VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping ... 1-3 GA, also known as advanced dry age-related macular degeneration, affects ...

Bausch + Lomb Corporation (NYSE ... XIIDRA is a treatment for dry eye disease while MEIBO is the first and only prescription eye drop that directly targets tear evaporation to treat the signs ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

Pre-tax losses at the main Irish unit of eye care product firm, Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX: BLCO), an established player in the eye health sector with ... GA, a form of advanced dry age-related macular degeneration, impacts around ...